Compass Therapeutics Investor Presentation Deck

Phase 1b CTX-009 Combination Study Tumor Growth (%) 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% -10.0% -20.0% -30.0% -40.0% -50.0% -60.0% -70.0% 36.8% COMPASS THERAPEUTICS 22.7% 16.3% 7.4% 0.0% 17 evaluable patients as of November 30, 2021 CTX-009 + paclitaxel or CTX-009 + irinotecan All patients dosed at 10 or 12.5 mg/kg -0.7% -10.4% -12.7% -17.0% -18.3% -19.7% -20.6% -28.0% -31.4% o Gastric CRC -34.9% Cholangio Pancreatic Other -41.4% -61.6% 12

View entire presentation